Platelets as Biomarkers of Coronary Artery Disease

Abstract

Primary and secondary prevention of cardiovascular disease remain a public health priority. Effective risk stratification of patients is a central requisite for effective preventative care and several scoring systems incorporating biomarkers have been used for prognostication in patients to guide intervention decisions. Thrombosis of atherosclerotic coronary arteries is the main mechanism behind the acute coronary syndromes and since platelets play a pivotal role in the pathogenesis of thrombosis, atherogenesis, and angiogenesis, platelet-derived biomarkers are an attractive concept. This review assesses the potential and the limitations of a range of platelet-based assays as biomarkers for coronary artery disease.

Keywords

platelets - platelet function - biomarker - cardiovascular disease

• References

• 1 Lozano R, Naghavi M, Foreman K , et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859) 2095-2128
• 2 Jackson SP. Arterial thrombosis—insidious, unpredictable and deadly. Nat Med 2011; 17 (11) 1423-1436
• 3 Montgomery JE, Brown JR. Metabolic biomarkers for predicting cardiovascular disease. Vasc Health Risk Manag 2013; 9: 37-45
• 4 Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111 (25) 3481-3488
• 5 Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013; 93 (1) 327-358
• 6 Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22 (9) 1381-1389
• 7 Monroe DM, Hoffman M. What does it take to make the perfect clot?. Arterioscler Thromb Vasc Biol 2006; 26 (1) 41-48
• 8 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85 (6) 958-965
• 9 Heemskerk JWM, Mattheij NJA, Cosemans JMEM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013; 11 (1) 2-16
• 10 Kuijpers MJE, Munnix IC, Cosemans JM , et al. Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. Microcirculation 2008; 15 (4) 269-282
• 11 Bennett JS. Platelet-fibrinogen interactions. Ann N Y Acad Sci 2001; 936: 340-354
• 12 Alshehri OM, Hughes CE, Montague S , et al. Fibrin activates GPVI in human and mouse platelets. Blood 2015; 126 (13) 1601-1608
• 13 Ferroni P, Vazzana N, Riondino S, Cuccurullo C, Guadagni F, Davì G. Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal 2012; 17 (10) 1447-1485
• 14 Swieringa F, Kuijpers MJE, Heemskerk JWM, van der Meijden PEJ. Targeting platelet receptor function in thrombus formation: the risk of bleeding. Blood Rev 2014; 28 (1) 9-21
• 15 Koyama H, Maeno T, Fukumoto S , et al. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 2003; 108 (5) 524-529
• 16 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115 (12) 3378-3384
• 17 Huo Y, Schober A, Forlow SB , et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9 (1) 61-67
• 18 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357 (24) 2482-2494
• 19 Vorchheimer DA, Becker R. Platelets in atherothrombosis. Mayo Clin Proc 2006; 81 (1) 59-68
• 20 Sharma G, Berger JS. Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data. J Thromb Thrombolysis 2011; 32 (2) 201-208
• 21 D'Agostino Sr RB, Grundy S, Sullivan LM, Wilson P ; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286 (2) 180-187
• 22 Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111 (2) 383-390
• 23 Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino Sr R, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1 (2) 92-97
• 24 Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform?. J Am Coll Cardiol 2003; 41 (9) 1475-1479
• 25 Falk E, Sillesen H, Muntendam P, Fuster V. The high-risk plaque initiative: primary prevention of atherothrombotic events in the asymptomatic population. Curr Atheroscler Rep 2011; 13 (5) 359-366
• 26 Fernández-Ortiz A, Jiménez-Borreguero LJ, Peñalvo JL , et al. The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design. Am Heart J 2013; 166 (6) 990-998
• 27 Budoff MJ, Diamond GA, Raggi P , et al. Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography. Circulation 2002; 105 (15) 1791-1796
• 28 Eapen DJ, Ghasemzadeh N, MacNamara JP, Quyyumi A. The evaluation of novel biomarkers and the multiple biomarker approach in the prediction of cardiovascular disease. Curr Cardiovasc Risk Rep 2014; 8: 408-411
• 29 Aldous SJ. Cardiac biomarkers in acute myocardial infarction. Int J Cardiol 2013; 164 (3) 282-294
• 30 Liuzzo G, Biasucci LM, Gallimore JR , et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999; 34 (6) 1696-1703
• 31 Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004; 25 (5) 401-408
• 32 Kervinen H, Palosuo T, Manninen V, Tenkanen L, Vaarala O, Mänttäri M. Joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J 2001; 141 (4) 580-585
• 33 Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103 (13) 1813-1818
• 34 Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109 (11) 1349-1353
• 35 Ridker PM, Danielson E, Fonseca FA , et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21) 2195-2207
• 36 Kaptoge S, Di Angelantonio E, Pennells L , et al; Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367 (14) 1310-1320
• 37 Di Angelantonio E, Gao P, Pennells L , et al; Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307 (23) 2499-2506
• 38 Looney SW, Hagan JL. Statistical methods for assessing biomarkers and analyzing biomarker data. In: Rao CR, Miller J, Rao DC, eds. Handbook of Statistics. Volume 27. Elsevier: 2007: 109-147
• 39 Mayeux R. Biomarkers: potential uses and limitations. NeuroRx 2004; 1 (2) 182-188
• 40 Strimbu K, Tavel JA. What are biomarkers?. Curr Opin HIV AIDS 2010; 5 (6) 463-466
• 41 Hoefer IE, Sels JW, Jukema JW , et al. Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study. Clin Res Cardiol 2013; 102 (11) 847-856
• 42 Kang J-G, Patino WD, Matoba S, Hwang PM. Genomic analysis of circulating cells: a window into atherosclerosis. Trends Cardiovasc Med 2006; 16 (5) 163-168
• 43 Lindsay CR, Edelstein LC. MicroRNAs in platelet physiology and function. Semin Thromb Hemost 2016; 42 (3) 215-222
• 44 Wykrzykowska JJ, Garcia-Garcia HM, Goedhart D, Zalewski A, Serruys PW. Differential protein biomarker expression and their time-course in patients with a spectrum of stable and unstable coronary syndromes in the Integrated Biomarker and Imaging Study-1 (IBIS-1). Int J Cardiol 2011; 149 (1) 10-16
• 45 Bahou WF. Genetic dissection of platelet function in health and disease using systems biology. Hematol Oncol Clin North Am 2013; 27 (3) 443-463
• 46 Tchebiner JZ, Nutman A, Boursi B , et al. Diagnostic and prognostic value of thrombocytosis in admitted medical patients. Am J Med Sci 2011; 342 (5) 395-401
• 47 van der Bom JG, Heckbert SR, Lumley T , et al. Platelet count and the risk for thrombosis and death in the elderly. J Thromb Haemost 2009; 7 (3) 399-405
• 48 Gary T, Pichler M, Belaj K , et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS ONE 2013; 8 (7) e67688
• 49 Ozcan Cetin EH, Cetin MS, Aras D , et al. Platelet to lymphocyte ratio as a prognostic marker of in-hospital and long-term major adverse cardiovascular events in ST-segment elevation myocardial infarction (epub ahead of print). Angiology 2015;pii: 0003319715591751; doi: 10.1177/0003319715591751
• 50 Oylumlu M, Yıldız A, Oylumlu M , et al. Platelet-to-lymphocyte ratio is a predictor of in-hospital mortality patients with acute coronary syndrome. Anatol J Cardiol 2015; 15 (4) 277-283
• 51 Kurtul A, Murat SN, Yarlioglues M , et al. Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. Am J Cardiol 2014; 114 (7) 972-978
• 52 Panova-Noeva M, Schulz A, Hermanns MI, Grossmann V, Pefani E, Spronk HMH , et al. Sex-specific differences in genetic and nongenetic determinants of mean platelet volume: results from the Gutenberg Health Study. Blood 2016; 127 (2) 251-259
• 53 Goncalves SC, Labinaz M, Le May M , et al. Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. Am J Cardiol 2011; 107 (2) 204-209
• 54 Ju HY, Kim JK, Hur SM , et al. Could mean platelet volume be a promising biomarker of progression of chronic kidney disease?. Platelets 2015; 26 (2) 143-147
• 55 Ki YJ, Park S, Ha SI, Choi DH, Song H. Usefulness of mean platelet volume as a biomarker for long-term clinical outcomes after percutaneous coronary intervention in Korean cohort: a comparable and additive predictive value to high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide. Platelets 2014; 25 (6) 427-432
• 56 Lai HM, Xu R, Yang YN , et al. Association of mean platelet volume with angiographic thrombus burden and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv 2015; 85 (Suppl. 01) 724-733
• 57 Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Katdare AD, Inamdar AK. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol 2006; 59 (2) 146-149
• 58 Guthikonda S, Lev EI, Patel R , et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 5 (3) 490-496
• 59 Guthikonda S, Alviar CL, Vaduganathan M , et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52 (9) 743-749
• 60 Chu SG, Becker RC, Berger PB , et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8 (1) 148-156
• 61 Tavil Y, Sen N, Yazici HU, Hizal F, Abaci A, Cengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2007; 120 (2) 245-250
• 62 Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J 2001; 22 (17) 1561-1571
• 63 Zhang Y , et al. Reticulated platelets are associated with long-term outcomes of premature coronary artery disease following percutaneous coronary intervention. Experimental and Clinical Cardiology 2014; 20: 145-163
• 64 Ibrahim H, Schutt RC, Hannawi B, DeLao T, Barker CM, Kleiman NS. Association of immature platelets with adverse cardiovascular outcomes. J Am Coll Cardiol 2014; 64 (20) 2122-2129
• 65 Rinder HM, Schuster JE, Rinder CS, Wang C, Schweidler HJ, Smith BR. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998; 91 (4) 1288-1294
• 66 Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet 2015; 386 (9990) 292-302
• 67 Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012; 18 (33) 5197-5214
• 68 Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e89S-e119S
• 69 Osnabrugge RL, Head SJ, Zijlstra F , et al. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Genet Med 2015; 17 (1) 3-11
• 70 Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353 (22) 2373-2383
• 71 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329) 71-86
• 72 Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351 (9098) 233-241
• 73 Mangiacapra F, Barbato E, Patti G , et al. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2010; 3 (3) 318-323
• 74 Zhao XY, Wang XF, Zhang JY, Du YY, Yang HB. Effect of the composition of atherosclerotic plaques and rate of platelet aggregation on elevation of serum levels of cardiac troponin T after percutaneous coronary interventions. J Interv Cardiol 2012; 25 (5) 433-438
• 75 Zhang HZ, Kim MH, Jeong YH. Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets 2014; 25 (4) 292-299
• 76 Patti G, Mangiacapra F, Ricottini E , et al. Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study). Am J Cardiol 2013; 111 (12) 1739-1744
• 77 Mangiacapra F, Bartunek J, Bijnens N , et al. Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. J Thromb Haemost 2012; 10 (12) 2452-2461
• 78 Park DW, Ahn JM, Song HG , et al. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2013; 165 (1) 34-42.e1
• 79 Mangiacapra F, Peace A, Barbato E , et al. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. Platelets 2014; 25 (5) 348-356
• 80 Mehta SR, Bassand JP, Chrolavicius S , et al; CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363 (10) 930-942
• 81 Kim C, Ye F, Ginsberg MH. Regulation of integrin activation. Annu Rev Cell Dev Biol 2011; 27: 321-345
• 82 Kasirer-Friede A, Kahn ML, Shattil SJ. Platelet integrins and immunoreceptors. Immunol Rev 2007; 218: 247-264
• 83 Berny-Lang MA, Frelinger III AL, Barnard MR, Michelson AD, In: Michelson AD. ed. Platelets. 3rd ed. London: Academic Press; 2013: 581-602
• 84 McEver RP, Cummings RD. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997; 100 (3) 485-491
• 85 Varki A. Selectin ligands: will the real ones please stand up?. J Clin Invest 1997; 100 (11, Suppl): S31-S35
• 86 Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 1999; 81 (1) 1-7
• 87 Evangelista V, Smyth SS. Platelets. 3rd ed. In: Michelson AD, ed. London: Academic Press; 2013: 295-312
• 88 Massaguer A, Engel P, Pérez-del-Pulgar S, Bosch J, Pizcueta P. Production and characterization of monoclonal antibodies against conserved epitopes of P-selectin (CD62P). Tissue Antigens 2000; 56 (2) 117-128
• 89 Ramström S, Södergren AL, Tynngård N, Lindahl TL. Platelet function determined by flow cytometry: new perspectives?. Semin Thromb Hemost 2016; 42 (3) 268-281
• 90 Klinkhardt U, Harder S. Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function?. Semin Thromb Hemost 2005; 31 (4) 400-403
• 91 Granja T, Schad J, Schüssel P , et al. Using six-colour flow cytometry to analyse the activation and interaction of platelets and leukocytes—A new assay suitable for bench and bedside conditions. Thromb Res 2015; 136 (4) 786-796
• 92 Barnard MR, Krueger LA, Frelinger AL, Furman MI, Michelson AD. Whole blood analysis of leukocyte-platelet aggregates. Current protocols in cytometry 2003; 24 6.15:6.15.1–6.15.8; DOI: 10.1002/0471142956.cy0615s24
• 93 Xu XX, Gao XH, Pan R, Lu D, Dai Y. A simple adhesion assay for studying interactions between platelets and endothelial cells in vitro. Cytotechnology 2010; 62 (1) 17-22
• 94 Tantry US, Bliden KP, Suarez TA, Kreutz RP, Dichiara J, Gurbel PA. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. Platelets 2010; 21 (5) 360-367
• 95 Schultheiss HP, Tschoepe D, Esser J , et al. Large platelets continue to circulate in an activated state after myocardial infarction. Eur J Clin Invest 1994; 24 (4) 243-247
• 96 Yip H-K, Chang LT, Sun CK , et al. Platelet activity is a biomarker of cardiac necrosis and predictive of untoward clinical outcomes in patients with acute myocardial infarction undergoing primary coronary stenting. Circ J 2006; 70 (1) 31-36
• 97 Coulter SA, Cannon CP, Ault KA , et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation 2000; 101 (23) 2690-2695
• 98 Furman MI, Benoit SE, Barnard MR , et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31 (2) 352-358
• 99 Kappelmayer J, Nagy Jr B, Miszti-Blasius K, Hevessy Z, Setiadi H. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med 2004; 42 (5) 475-486
• 100 Tschoepe D, Schultheiss HP, Kolarov P , et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88 (1) 37-42
• 101 Gawaz M, Neumann FJ, Ott I, May A, Rüdiger S, Schömig A. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coron Artery Dis 1997; 8 (3–4) 121-128
• 102 Kabbani SS, Watkins MW, Ashikaga T , et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104 (2) 181-186
• 103 Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Sobel BE, Schneider DJ. Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am J Cardiol 2003; 91 (7) 876-878
• 104 Ault KA, Cannon CP, Mitchell J , et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J Am Coll Cardiol 1999; 33 (3) 634-639
• 105 Frelinger III AL, Michelson AD, Wiviott SD , et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106 (2) 219-226
• 106 Gawaz M, Neumann FJ, Ott I, May A, Schömig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996; 94 (3) 279-285
• 107 Neumann FJ, Gawaz M, Dickfeld T , et al. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 1997; 29 (7) 1515-1519
• 108 Floyd CN, Goodman T, Becker S , et al. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. Br J Clin Pharmacol 2014; 78 (2) 320-328
• 109 Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322 (22) 1549-1554
• 110 Vanschoonbeek K, Feijge MA, Keuren JF , et al. Thrombin-induced hyperactivity of platelets of young stroke patients: involvement of thrombin receptors in the subject-dependent variability in Ca2+ signal generation. Thromb Haemost 2002; 88 (6) 931-937
• 111 Konstantopoulos K, Grotta JC, Sills C, Wu KK, Hellums JD. Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb Haemost 1995; 74 (5) 1329-1334
• 112 Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106 (8) 2723-2729
• 113 Qayyum R, Becker DM, Yanek LR , et al. Greater collagen-induced platelet aggregation following cyclooxygenase 1 inhibition predicts incident acute coronary syndromes. Clin Transl Sci 2015; 8 (1) 17-22
• 114 McBane II RD, Karnicki K, Tahirkheli N, Miller RS, Owen WG. Platelet characteristics associated with coronary artery disease. J Thromb Haemost 2003; 1 (6) 1296-1303
• 115 Chung AWY, Radomski A, Alonso-Escolano D , et al. Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases. Br J Pharmacol 2004; 143 (7) 845-855
• 116 von Brühl M-L, Stark K, Steinhart A , et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209 (4) 819-835
• 117 Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Murohara T, Imaizumi T. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol 2005; 45 (8) 1280-1286
• 118 Zhang X, Zhan D, Shin HY. Integrin subtype-dependent CD18 cleavage under shear and its influence on leukocyte-platelet binding. J Leukoc Biol 2013; 93 (2) 251-258
• 119 Zeller JA, Lenz A, Eschenfelder CC, Zunker P, Deuschl G. Platelet-leukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterioscler Thromb Vasc Biol 2005; 25 (7) 1519-1523
• 120 Naruko T, Ueda M, Haze K , et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106 (23) 2894-2900
• 121 Di Serafino L, Sarma J, Dierickx K , et al. Monocyte-platelets aggregates as cellular biomarker of endothelium-dependent coronary vasomotor dysfunction in patients with coronary artery disease. J Cardiovasc Transl Res 2014; 7 (1) 1-8
• 122 Rutten B, Tersteeg C, Vrijenhoek JE , et al. Increased platelet reactivity is associated with circulating platelet-monocyte complexes and macrophages in human atherosclerotic plaques. PLoS ONE 2014; 9 (8) e105019
• 123 Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104 (13) 1533-1537
• 124 Hua VM, Abeynaike L, Glaros E , et al. Necrotic platelets provide a procoagulant surface during thrombosis. Blood 2015; 126 (26) 2852-2862
• 125 Hua VM, Chen VMY. Procoagulant platelets and the pathways leading to cell death. Semin Thromb Hemost 2015; 41 (4) 405-412
• 126 Prodan CI, Stoner JA, Cowan LD, Dale GL. Higher coated-platelet levels are associated with stroke recurrence following nonlacunar brain infarction. J Cereb Blood Flow Metab 2013; 33 (2) 287-292
• 127 Kirkpatrick AC, Tafur AJ, Vincent AS, Dale GL, Prodan CI. Coated-platelets improve prediction of stroke and transient ischemic attack in asymptomatic internal carotid artery stenosis. Stroke 2014; 45 (10) 2995-3001
• 128 Rechner AR. Platelet function testing in clinical diagnostics. Hamostaseologie 2011; 31 (2) 79-87
• 129 Gorog DA, Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. J Am Coll Cardiol 2013; 61 (21) 2115-2129
• 130 E. Kehrel B, F. Brodde M. State of the art in platelet function testing. Transfus Med Hemother 2013; 40 (2) 73-86
• 131 Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag 2015; 11: 133-148
• 132 Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: Linking proinflammatory responses to procoagulant state. Thromb Res 2013; 131 (3) 191-197